Taylor Wealth Management Partners’s Krystal Biotech KRYS Stock Holding History

Taylor Wealth Management Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$296K	Sell	4,514 -851	-16%	-$52.9K	0.17%	49
2022 Q1	$357K	Buy	5,365 +50	+0.9%	+$3.12K	0.14%	53
2021 Q4	$372K	Sell	5,315 -1,300	-20%	-$75.7K	0.13%	51
2021 Q3	$345K	Hold	6,615	–	–	0.12%	57
2021 Q2	$450K	Buy	6,615 +200	+3%	+$14K	0.16%	51
2021 Q1	$494K	Buy	6,415 +637	+11%	+$46.3K	0.18%	57
2020 Q4	$347K	Buy	+5,778	New	+$289K	0.13%	51

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Taylor Wealth Management Partners's KRYS Position: Q2 2022 in Review

Taylor Wealth Management Partners reduced its Krystal Biotech (KRYS) stake by 16% in Q2 2022, selling an estimated $52.9K and leaving 4,514 shares worth $296K. The position accounts for 0.17% of the portfolio, ranked #49.

Taylor Wealth Management Partners first reported a position in KRYS in Q4 2020 and has held it in 7 quarters since. The position peaked at $494K in Q1 2021. 137 funds tracked by Wall St. Rank hold KRYS as of Q2 2022.

Taylor Wealth Management Partners held 4,514 shares of Krystal Biotech worth $296K as of Q2 2022.
Taylor Wealth Management Partners sold 851 Krystal Biotech shares in Q2 2022, an estimated $52.9K.
Krystal Biotech made up 0.17% of Taylor Wealth Management Partners's portfolio in Q2 2022, its #49 holding.
Taylor Wealth Management Partners first reported a position in Krystal Biotech in Q4 2020 and has held it in 7 quarters since.
Taylor Wealth Management Partners's Krystal Biotech position peaked at $494K in Q1 2021.
137 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2022.

Based on Taylor Wealth Management Partners's 13F filing for Q2 2022, filed 12 Aug 2022.